Exactly ! Mithra shares down 70% ytd. They’re cash poor. The low take up of Nextellis in USA being a big contributor to their expectations along with Mayne shareholders.The profit positive first year outlook has come and gone. The $200m revenue now appears Pie in the Sky for this revolutionary Pill . Menopause market is far less competitive and yet market is huge and growing. Since Mithra is already at Phase 3 trials for FDA approval, should this product prove successful it is blue sky potential. Anybody thinking Mayne will get US distribution rights because they have 10% of company is barking up the wrong tree. We have been a failure with Nextellis. The facts are should this Donesta product meet expectations Mithra will associate with the highest bidder and best distribution company suitable in USA. Simple as that. As long as we conduct extremely high due diligence and with cash surplus invested to gain a major shareholding we could be front runners.
MYX Price at posting:
29.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)